Related Experiment Videos
[Transcutaneous estradiol treatment in the climacteric]
1Svendborg Sygehus, gynaekologisk-obstetrisk afdeling.
Ugeskrift for Laeger
|September 3, 1990
Summary
Transcutaneous estradiol and medroxyprogesterone effectively treated menopausal symptoms like hot flashes. Most women tolerated the therapy well, with few side effects, and many desired continued treatment for symptom relief.
Area of Science:
- Reproductive Endocrinology
- Menopause Management
Background:
- Menopausal symptoms significantly impact women's quality of life.
- Hormone therapy is a common treatment for menopausal symptoms.
Purpose of the Study:
- To evaluate the efficacy and safety of transcutaneous estradiol supplemented with medroxyprogesterone in women with menopausal symptoms.
- To assess hormonal changes and biochemical markers during treatment.
Main Methods:
- An open, uncontrolled, prospective study involving 34 women with menopausal symptoms.
- Treatment involved transcutaneous estradiol for four months, with medroxyprogesterone from day 12-26 monthly.
- Kupperman's menopausal index was used to assess symptom severity.
Main Results:
- Significant improvement in sweating, hot flushes, and overall menopausal complaints.
- Serum estradiol initially rose to follicular phase levels, then decreased by month four without symptom worsening.
- No significant changes in steroid-hormone-binding globulin, lipids, or body weight were observed.
- Most patients experienced no or transient side effects; dose reduction managed mastalgia.
Conclusions:
- Transcutaneous estradiol with medroxyprogesterone is effective for managing menopausal symptoms.
- The treatment is generally well-tolerated, with a high desire for continuation among patients.
- Placement of transdermal patches did not influence treatment outcomes.